SlideShare a Scribd company logo
1 of 58
February 26, 2008 Bradley Merrill Thompson Sponsor-CRO Relationships:  Managing Risk
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What is a Contract Research Organization? ,[object Object],[object Object],[object Object],[object Object]
SMOs Defined ,[object Object],[object Object],[object Object],[object Object]
CROs v SMOs Sponsor Sponsor’s Agent (CRO) Researcher’sAgent (SMO) Research Site/ Investigator
CRO Industry ,[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CRO Clinical Trial Services  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Potential Advantages of CROs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Potential Risks of Outsourcing to CROs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Delegation of Authority to CRO ,[object Object],[object Object],[object Object],[object Object],[object Object]
Delegation of Authority to CRO Portion of Transfer of Obligations form: X Ensuring the FDA and all participating Investigators are promptly informed of significant new adverse effects or risks with respect to the Study Materials X Maintaining an effective IND with respect to the Study X Ensuring that the Study is conducted in accordance with the Protocol X Ensuring proper monitoring of the Study X Providing Investigators with the information they need to conduct the Study properly X Selecting qualified Investigators 212 CRF  312.50 General responsibilities of sponsors Transferred to CRO Maintained by Sponsor Sponsor Responsibility
Delegation of Authority to CRO ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Traditional Pattern of Outsourcing Integration ,[object Object],[object Object],[object Object],[object Object],[object Object],Strategic Alliance Preferred Supplier ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Partnership Source: August 2004, Goldman Sachs Research ,[object Object],Transactional
Checks and Balances ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Secondary Vendors Primary Vendor
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CRO Selection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CRO Selection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
QA Questions to Ask ,[object Object],[object Object],[object Object],[object Object],Winther
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Common Project Risks ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Source: Thomson CenterWatch 2005 Survey of 612 Investigative Sites in the U.S. Factor Most Often Causing Study Delays United States
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Metrics--Why Measure? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CRO and Sponsor Relationships ,[object Object],[object Object],[object Object],[object Object],[object Object]
Metrics in a CRO Relationship CRO Engagement RFP and Due Diligence Contracting Execution of work Evaluation Metric Creation Key Performance Indicators Critical Success Factors Specific Performance Indicators Discussion Senior Committee Junior Committee Discussion Analysis Measurement Feedback & Adjustment Feedback Planning Metric Use
Key Metrics for Early Identification of Project Risk ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Varawalla
Example Metric Definition Table *All days specified are elapsed time Cuddigan & King Clinical data management system (CDMS) Clinical trial management system (CTMS) Data Source 5 days Average number of days from patient visit to lab data available in CDMS Visit data to lab data available in database 60 days (mean); 90 days (oncology) Number of days from final protocol approval by sponsor to first patient enrolled at first site Final protocol to first patient recruited Achievement of key project timelines Target * Definition Related Metrics KPI
Example Metric Definition Table, contd. *All days specified are elapsed time Cuddigan & King CTMS CDMS Data Source 21 days Number of days between database lock and final approval study report Database lock to final study report 5 days Number of days from LPLV at site to database locked Last patient last visit (LPLV) to database lock Target * Definition Related Metrics KPI
Example Metric Definition Table, contd. Cuddigan & King CTMS Percent of sites enrolled that recruits 1 subject within one month of initiation visit Percent of non-performing centers Data manager Number of database errors found on database audit/total number of data fields audited Database error rate Achievement of target quality standards Data Source Definition Related Metrics KPI
Example Metric Definition Table, contd. Cuddigan & King Finance Number of change orders approved after initial contract sign-off Number of change orders Finance Total project fees after final invoice paid, compared with initial contract value (includes pass-through costs) Final actual contract cost as percent of initial contract value Compliance with agreed contract value Data Source Definition Related Metrics KPI
Metrics in a CRO Relationship CRO Engagement RFP and Due Diligence Contracting Execution of work Evaluation Metric Creation Key Performance Indicators Critical Success Factors Specific Performance Indicators Discussion Senior Committee Junior Committee Discussion Analysis Measurement Feedback & Adjustment Feedback Planning Metric Use
How Do We Use Metrics? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Utility in Managing Sites ,[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Third party vendors (e.g., labs) SPONSOR SUBJECT FDA IRB** DSMB,  MRC, etc CRO* INVESTIGATOR INSTITUTION/ CLINICAL SITE CTA Informed Consent 1572 CTA CTAs * Contracts on behalf of sponsor (donated by dotted line) ** May or may not be a written agreement - depends on whether IRB is commercial, local, centralized, etc Services Agreements Blue  = CTA Orange  = Service Agreement Green  = Regulatory “agreement”
Ability to Bind Sponsor to CTAs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ability to Bind Sponsor to CTAs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Change Orders ,[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Personnel ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Managing Personnel ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Watch for Red Flags ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Vogel
Strategy for Avoiding Delays ,[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Managing Communications ,[object Object],[object Object],[object Object],[object Object]
Preferred Provider Agreement Relationship Management Model—Joint Committees Thomis & Desai Project Team 1 Project Team 2 Project Team 3 Project Team 4 Governance/Steering Committee (VPs) Operational Committee (Directors)
Speaking The Same Language ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Proactively Avoiding Disputes ,[object Object],[object Object],[object Object],[object Object],[object Object]
Resolving Payment Disputes ,[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Post Study Learning ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Topics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Take Aways ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Questions?

More Related Content

What's hot

Essential documents and_managing_trial_files
Essential documents and_managing_trial_filesEssential documents and_managing_trial_files
Essential documents and_managing_trial_filesLanka Praneeth
 
Risk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on SitesRisk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on SitesWool Consuting Group Inc.
 
Sponsor-CRO Relationships
Sponsor-CRO RelationshipsSponsor-CRO Relationships
Sponsor-CRO RelationshipsDavid Selkirk
 
Monitoring and auditing in clinical trials
Monitoring and auditing in clinical trialsMonitoring and auditing in clinical trials
Monitoring and auditing in clinical trialsJyotsna Kapoor
 
Monitoring of clinical trials
Monitoring of clinical trialsMonitoring of clinical trials
Monitoring of clinical trialskattamurilakshmi
 
Clinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLSClinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLSKatalyst HLS
 
Essential documents
Essential documentsEssential documents
Essential documentsRajeev Sahai
 
Project management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 mayProject management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 maySanjay Akhani
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSKatalyst HLS
 
Audit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectivesAudit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectivesDr Prashant Bodhe
 
Roles and Responsibilities of sponsor, CRO, and investigator
Roles and Responsibilities of sponsor, CRO, and investigator Roles and Responsibilities of sponsor, CRO, and investigator
Roles and Responsibilities of sponsor, CRO, and investigator MOHAMMEDSALEEMJM
 

What's hot (20)

Essential documents and_managing_trial_files
Essential documents and_managing_trial_filesEssential documents and_managing_trial_files
Essential documents and_managing_trial_files
 
Clinical trial monitoring
Clinical trial monitoringClinical trial monitoring
Clinical trial monitoring
 
Risk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on SitesRisk Based Monitoring in Clinical Trials - Impact on Sites
Risk Based Monitoring in Clinical Trials - Impact on Sites
 
Sponsor-CRO Relationships
Sponsor-CRO RelationshipsSponsor-CRO Relationships
Sponsor-CRO Relationships
 
Monitoring and auditing in clinical trials
Monitoring and auditing in clinical trialsMonitoring and auditing in clinical trials
Monitoring and auditing in clinical trials
 
Clinical trial process
Clinical trial processClinical trial process
Clinical trial process
 
Monitoring of clinical trials
Monitoring of clinical trialsMonitoring of clinical trials
Monitoring of clinical trials
 
Cdm
CdmCdm
Cdm
 
Clinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLSClinical Data Management Process Overview_Katalyst HLS
Clinical Data Management Process Overview_Katalyst HLS
 
Essential documents
Essential documentsEssential documents
Essential documents
 
Opportunities in Clinical Research
Opportunities in Clinical ResearchOpportunities in Clinical Research
Opportunities in Clinical Research
 
Project management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 mayProject management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 may
 
Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
TMF PDF.pdf
TMF PDF.pdfTMF PDF.pdf
TMF PDF.pdf
 
Audit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectivesAudit monitoring and inspections cro perspectives
Audit monitoring and inspections cro perspectives
 
Roles and Responsibilities of sponsor, CRO, and investigator
Roles and Responsibilities of sponsor, CRO, and investigator Roles and Responsibilities of sponsor, CRO, and investigator
Roles and Responsibilities of sponsor, CRO, and investigator
 
How to report an SAE
How to report an SAEHow to report an SAE
How to report an SAE
 
Site qualification visit
Site qualification visitSite qualification visit
Site qualification visit
 
Cra responsebility
Cra responsebilityCra responsebility
Cra responsebility
 

Similar to Pharma-CRO Relationships Managing Risk A Lawyer\'s View

Highlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationHighlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationExL Pharma
 
Vendor Alliance: Cultivating the Most Beneficial Vendor Relationships
Vendor Alliance: Cultivating the Most Beneficial Vendor RelationshipsVendor Alliance: Cultivating the Most Beneficial Vendor Relationships
Vendor Alliance: Cultivating the Most Beneficial Vendor Relationshipseyalsron
 
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small BiotechMary Syto
 
Medelis Overview - A Specialized Oncology CRO - Q315
Medelis Overview - A Specialized Oncology CRO - Q315Medelis Overview - A Specialized Oncology CRO - Q315
Medelis Overview - A Specialized Oncology CRO - Q315Jim Sagar
 
Compliant Dissemination of Promotional and Educational Material
Compliant Dissemination of Promotional and Educational MaterialCompliant Dissemination of Promotional and Educational Material
Compliant Dissemination of Promotional and Educational MaterialGood Promotional Practices
 
Real-Life Compliance Solutions: Part I
Real-Life Compliance Solutions: Part IReal-Life Compliance Solutions: Part I
Real-Life Compliance Solutions: Part IProlifiq Software
 
Highlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsHighlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsExL Pharma
 
Highlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceHighlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceExL Pharma
 
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!mwright1
 
2017 Projects Kenneth Wu
2017 Projects Kenneth Wu2017 Projects Kenneth Wu
2017 Projects Kenneth WuKenneth Wu
 
ACRP-Clinical-Researcher-RBM-CRO-Perspective-Medpace
ACRP-Clinical-Researcher-RBM-CRO-Perspective-MedpaceACRP-Clinical-Researcher-RBM-CRO-Perspective-Medpace
ACRP-Clinical-Researcher-RBM-CRO-Perspective-MedpaceAlex Artyomenko
 
Vendor Management - Compliance Checklist Manifesto Series
Vendor Management - Compliance Checklist Manifesto SeriesVendor Management - Compliance Checklist Manifesto Series
Vendor Management - Compliance Checklist Manifesto SeriesContinuity Control
 
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...SC CTSI at USC and CHLA
 
Investigator Initated Trials (IIT)
Investigator Initated Trials (IIT)Investigator Initated Trials (IIT)
Investigator Initated Trials (IIT)Ran Frenkel
 
Global Clinical Trials: Best Practices & Common Pitfalls
Global Clinical Trials: Best Practices & Common PitfallsGlobal Clinical Trials: Best Practices & Common Pitfalls
Global Clinical Trials: Best Practices & Common PitfallsImperial CRS
 
OCT-East-Programme-for-Web-1
OCT-East-Programme-for-Web-1OCT-East-Programme-for-Web-1
OCT-East-Programme-for-Web-1David Kiger
 

Similar to Pharma-CRO Relationships Managing Risk A Lawyer\'s View (20)

Highlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationHighlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & Communication
 
Vendor Alliance: Cultivating the Most Beneficial Vendor Relationships
Vendor Alliance: Cultivating the Most Beneficial Vendor RelationshipsVendor Alliance: Cultivating the Most Beneficial Vendor Relationships
Vendor Alliance: Cultivating the Most Beneficial Vendor Relationships
 
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech
2015-11 Mary Syto CTS SoCal Challenges in Global Supply Mgmt in Small Biotech
 
Medelis Overview - A Specialized Oncology CRO - Q315
Medelis Overview - A Specialized Oncology CRO - Q315Medelis Overview - A Specialized Oncology CRO - Q315
Medelis Overview - A Specialized Oncology CRO - Q315
 
Compliant Dissemination of Promotional and Educational Material
Compliant Dissemination of Promotional and Educational MaterialCompliant Dissemination of Promotional and Educational Material
Compliant Dissemination of Promotional and Educational Material
 
Real-Life Compliance Solutions: Part I
Real-Life Compliance Solutions: Part IReal-Life Compliance Solutions: Part I
Real-Life Compliance Solutions: Part I
 
MAGI Presentation
MAGI PresentationMAGI Presentation
MAGI Presentation
 
Highlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsHighlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated Trials
 
What to expect from a CRO
What to expect from a CRO What to expect from a CRO
What to expect from a CRO
 
Highlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceHighlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP Compliance
 
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!
Having a Prosperous New Year with Your CRO: The Gift of a Great Contract!
 
2017 Projects Kenneth Wu
2017 Projects Kenneth Wu2017 Projects Kenneth Wu
2017 Projects Kenneth Wu
 
ACRP-Clinical-Researcher-RBM-CRO-Perspective-Medpace
ACRP-Clinical-Researcher-RBM-CRO-Perspective-MedpaceACRP-Clinical-Researcher-RBM-CRO-Perspective-Medpace
ACRP-Clinical-Researcher-RBM-CRO-Perspective-Medpace
 
Vendor Management - Compliance Checklist Manifesto Series
Vendor Management - Compliance Checklist Manifesto SeriesVendor Management - Compliance Checklist Manifesto Series
Vendor Management - Compliance Checklist Manifesto Series
 
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
 
Investigator Initated Trials (IIT)
Investigator Initated Trials (IIT)Investigator Initated Trials (IIT)
Investigator Initated Trials (IIT)
 
Global Clinical Trials: Best Practices & Common Pitfalls
Global Clinical Trials: Best Practices & Common PitfallsGlobal Clinical Trials: Best Practices & Common Pitfalls
Global Clinical Trials: Best Practices & Common Pitfalls
 
CRO - Clinical Vendor Oversight Webinar.
CRO - Clinical Vendor Oversight Webinar.CRO - Clinical Vendor Oversight Webinar.
CRO - Clinical Vendor Oversight Webinar.
 
Claims Triage
Claims TriageClaims Triage
Claims Triage
 
OCT-East-Programme-for-Web-1
OCT-East-Programme-for-Web-1OCT-East-Programme-for-Web-1
OCT-East-Programme-for-Web-1
 

Pharma-CRO Relationships Managing Risk A Lawyer\'s View

  • 1. February 26, 2008 Bradley Merrill Thompson Sponsor-CRO Relationships: Managing Risk
  • 2.
  • 3.
  • 4.
  • 5. CROs v SMOs Sponsor Sponsor’s Agent (CRO) Researcher’sAgent (SMO) Research Site/ Investigator
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. Delegation of Authority to CRO Portion of Transfer of Obligations form: X Ensuring the FDA and all participating Investigators are promptly informed of significant new adverse effects or risks with respect to the Study Materials X Maintaining an effective IND with respect to the Study X Ensuring that the Study is conducted in accordance with the Protocol X Ensuring proper monitoring of the Study X Providing Investigators with the information they need to conduct the Study properly X Selecting qualified Investigators 212 CRF 312.50 General responsibilities of sponsors Transferred to CRO Maintained by Sponsor Sponsor Responsibility
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Source: Thomson CenterWatch 2005 Survey of 612 Investigative Sites in the U.S. Factor Most Often Causing Study Delays United States
  • 23.
  • 24.
  • 25.
  • 26. Metrics in a CRO Relationship CRO Engagement RFP and Due Diligence Contracting Execution of work Evaluation Metric Creation Key Performance Indicators Critical Success Factors Specific Performance Indicators Discussion Senior Committee Junior Committee Discussion Analysis Measurement Feedback & Adjustment Feedback Planning Metric Use
  • 27.
  • 28. Example Metric Definition Table *All days specified are elapsed time Cuddigan & King Clinical data management system (CDMS) Clinical trial management system (CTMS) Data Source 5 days Average number of days from patient visit to lab data available in CDMS Visit data to lab data available in database 60 days (mean); 90 days (oncology) Number of days from final protocol approval by sponsor to first patient enrolled at first site Final protocol to first patient recruited Achievement of key project timelines Target * Definition Related Metrics KPI
  • 29. Example Metric Definition Table, contd. *All days specified are elapsed time Cuddigan & King CTMS CDMS Data Source 21 days Number of days between database lock and final approval study report Database lock to final study report 5 days Number of days from LPLV at site to database locked Last patient last visit (LPLV) to database lock Target * Definition Related Metrics KPI
  • 30. Example Metric Definition Table, contd. Cuddigan & King CTMS Percent of sites enrolled that recruits 1 subject within one month of initiation visit Percent of non-performing centers Data manager Number of database errors found on database audit/total number of data fields audited Database error rate Achievement of target quality standards Data Source Definition Related Metrics KPI
  • 31. Example Metric Definition Table, contd. Cuddigan & King Finance Number of change orders approved after initial contract sign-off Number of change orders Finance Total project fees after final invoice paid, compared with initial contract value (includes pass-through costs) Final actual contract cost as percent of initial contract value Compliance with agreed contract value Data Source Definition Related Metrics KPI
  • 32. Metrics in a CRO Relationship CRO Engagement RFP and Due Diligence Contracting Execution of work Evaluation Metric Creation Key Performance Indicators Critical Success Factors Specific Performance Indicators Discussion Senior Committee Junior Committee Discussion Analysis Measurement Feedback & Adjustment Feedback Planning Metric Use
  • 33.
  • 34.
  • 35.
  • 36. Third party vendors (e.g., labs) SPONSOR SUBJECT FDA IRB** DSMB, MRC, etc CRO* INVESTIGATOR INSTITUTION/ CLINICAL SITE CTA Informed Consent 1572 CTA CTAs * Contracts on behalf of sponsor (donated by dotted line) ** May or may not be a written agreement - depends on whether IRB is commercial, local, centralized, etc Services Agreements Blue = CTA Orange = Service Agreement Green = Regulatory “agreement”
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49. Preferred Provider Agreement Relationship Management Model—Joint Committees Thomis & Desai Project Team 1 Project Team 2 Project Team 3 Project Team 4 Governance/Steering Committee (VPs) Operational Committee (Directors)
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.

Editor's Notes

  1. By understanding what are the current trend in the industry we would all have a better feel for what we need to address. Clearly, this slide states the top 2 reasons the consumers are waiting longer for their drugs or devices.